Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Letizia Foroni

Showing results (61-70 of 84) with videos related to

Pageof 9
Sort By:
Blood|June 22, 2010
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myelomaIan H Gabriel, Ruhena Sergeant, Richard Szydlo, et al.
Haematologica|October 17, 2009
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemiaDragana Milojkovic, Emma Nicholson, Jane F Apperley, et al.
Blood|November 27, 2013
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemiaAdele K Fielding, Jacob M Rowe, Georgina Buck, et al.
Blood|August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocolMarc R Mansour, Maria L Sulis, Veronique Duke, et al.
Blood|February 25, 2011
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyAmr R Ibrahim, Lina Eliasson, Jane F Apperley, et al.
Blood|July 24, 2012
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemiaSara Ali, Ruhena Sergeant, Stephen G O'Brien, et al.
Blood|November 22, 2012
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myelomaAristeidis Chaidos, Chris P Barnes, Gillian Cowan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibDavid Marin, Alexandra Bazeos, Francois-Xavier Mahon, et al.
Haematologica|January 26, 2013
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trialDavid I Marks, Anthony V Moorman, Lucy Chilton, et al.
Pageof 9

Showing results (61-70 of 84) with videos related to

Sort By:
Pageof 9
Blood|June 22, 2010
Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myelomaIan H Gabriel, Ruhena Sergeant, Richard Szydlo, et al.
Haematologica|October 17, 2009
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemiaDragana Milojkovic, Emma Nicholson, Jane F Apperley, et al.
Blood|November 27, 2013
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemiaAdele K Fielding, Jacob M Rowe, Georgina Buck, et al.
Blood|August 4, 2010
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Timothy P Hughes, Andreas Hochhaus, Susan Branford, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocolMarc R Mansour, Maria L Sulis, Veronique Duke, et al.
Blood|February 25, 2011
Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapyAmr R Ibrahim, Lina Eliasson, Jane F Apperley, et al.
Blood|July 24, 2012
Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemiaSara Ali, Ruhena Sergeant, Stephen G O'Brien, et al.
Blood|November 22, 2012
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myelomaAristeidis Chaidos, Chris P Barnes, Gillian Cowan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 14, 2010
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibDavid Marin, Alexandra Bazeos, Francois-Xavier Mahon, et al.
Haematologica|January 26, 2013
The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trialDavid I Marks, Anthony V Moorman, Lucy Chilton, et al.
Pageof 9